Quantcast
Home > Quotes > SENS

Senseonics Holdings, Inc. Common Stock (SENS) Quote & Summary Data

SENS 
$4.7
*  
0.36
8.29%
Get SENS Alerts
*Delayed - data as of Sep. 24, 2018  -  Find a broker to begin trading SENS now
Exchange:AMEX
Industry: Capital Goods
Community Rating:
View:    SENS Pre-Market
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

1 Year Target
6
Today's High / Low
$ 4.70 / $ 4.45
Share Volume
2,657,082
90 Day Avg. Daily Volume
2,191,455
Previous Close
$ 4.34
52 Week High / Low
$ 5.29 / $ 2.36
Market Cap
827,325,772
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
0.34

Intraday Chart

Shares Traded

Share Volume:
2,657,082
90 Day Avg. Daily Volume:
2,191,455

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -0.64

Trading Range

The current last sale of $4.70 is 99.15% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 4.70 $ 5.29
 Low: $ 4.45 $ 2.36

ETFs with SENS as a Top 10 Holding*

Weighting ETF Name (Symbol) 100-Day Price Change (%)
0.72% The Obesity ETF (SLIM) +5.85 (18.20%)
*Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change.
**Green highlights the top performing ETF by % change in the past 100 days.

Company Description (as filed with the SEC)

We are a medical technology company focused on the design, development and commercialization of glucose monitoring products to improve the lives of people with diabetes by enhancing their ability to manage their disease with relative ease and accuracy. Our continuous glucose monitoring, or CGM, systems, Eversense and Eversense XL, are reliable, long-term, implantable CGM systems that we have designed to continually and accurately measure glucose levels in people with diabetes for a period of up to 90 and 180 days, respectively, as compared to six to fourteen days for currently available CGM systems. We believe Eversense and Eversense XL will provide people with diabetes with a more convenient method to monitor their glucose levels in comparison to the traditional method of self-monitoring of blood glucose, or SMBG, as well as currently available CGM systems. In our U.S.  ... More ...  


Risk Grade

Where does SENS fit in the risk graph?


Risk Grade Scale

Consensus Recommendation

Analyst Info